Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter ...
Morningstar

This Undervalued Stock Offers Investors a Rare Combination

Bio-Rad Laboratories BIO is something of a rarity: a small-cap company with a wide economic moat. The company develops products and solutions for the clinical diagnostics and life sciences industries, ...

Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down

BIO misses Q4 EPS estimates as margins shrank and shares slid 12%, despite revenue growth and a rebound in Clinical Diagnostics sales.

Bio-Rad Laboratories (BIO) Returns To Profitability With Diagnostics Rebound – Is The Turnaround Durable?

In February 2026, Bio-Rad Laboratories reported fourth-quarter 2025 sales of US$693.2 million and net income of US$720 million, marking a return to profitability after a prior-year loss, alongside ...

Bio-Rad outlines 2026 margin expansion and 0.5%-1.5% revenue growth guidance amid operational improvements

Q4 2025 Management View Jonathan DiVincenzo, President & COO, stated that Bio-Rad delivered results within revised guidance ...

Is It Time To Reassess Bio-Rad Laboratories (BIO) After Multi Year Share Price Weakness

If you are wondering whether Bio-Rad Laboratories is starting to look attractively priced after a rough few years, this ...

Bio-Rad earnings on deck as estimates drift lower ahead of report

Bio-Rad trades at nearly 30 times forward earnings despite recent losses, reflecting expectations for a turnaround as its ...

Bio-Rad Labs Shares Fall As Tight Research Funding Squeezes Margins

Bio-Rad Laboratories shares fell as the company faces margin pressure related to declining academic research funding. The stock slipped 10.6% to $261.43 Friday. Shares are down 14% over the past 12 ...
Zacks Investment Research on MSN

Bio-Rad Laboratories (BIO) Q4 earnings miss estimates

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.51 per share, missing the Zacks Consensus Estimate of $2.57 per share. This compares to earnings of $2.9 per share a year ago. These ...
Seeking Alpha

Bio-Rad: Uncertainties And Conservatism Continue To Hold Stock Back From Its Full Potential

Bio-Rad has been challenged by tough end-market conditions in life sciences tools, but the outlook for 2025 is better. The company's cautious approach has led to lackluster sales growth and margin ...
Investing.com South Africa

Bio-Rad shares tumble as Q4 earnings miss expectations

During the quarter, Bio-Rad recognized a substantial change in the fair market value of its investment in Sartorius AG, ...
SFGate

All in the family / Bio-Rad, 50 years later, is still doing business in its own way

Long before the genome was mapped, before investors went Internet crazy, even before color television, David and Alice Schwartz started a scientific supply company called Bio-Rad Laboratories. Now, 50 ...